Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
Lei Fan, Wen-Juan Zhang, Hui-Ping Li, Xiao-Hua Zeng, Yue-E Teng, Yue Gong, Xi Jin, Shen Zhao, Tao Sun, Wen-Yan Chen, Shu-Sen Wang, Jin Yang, Zhi-Gang Zhuang, Su-Jie Ni, Zhi-Xian He, De-Yuan Fu, Chuan-Gui Song, Zheng Lv, Qian-Nan Liang, Bao-Hua Yu, Jing Shi, Nan Wang, Xin-Rui Liang, Ning-Ning Zhang, Yun Wang, Peng Ji, Xi-Yu Liu, Li Chen, Min He, Yin Liu, Xin-Yi Sui, Lin-Xiaoxi Ma, Xiu-Zhi Zhu, Fan Yang, Li-Ping Ge, Song-Yang Wu, Jiong Wu, Ke-Da Yu, Guang-Yu Liu, Xin Hu, Yu Shen, Zheng Pang, Jian-Fei Wang, Fei Liang, Wen-Tao Yang, Zhong-Hua Wang, Yi-Zhou Jiang, Zhi-Ming Shao, BCTOP investigators
Cancer Cell 44(2) 355-365.e3
摘要
摘要
We report the results of LINUX (NCT05594095), a multicenter, randomized, controlled phase II platform trial aiming to identify effective precision treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer after resistance to cyclin-dependent kinase 4/6 inhibitor. A total of 105 patients were categorized into four similarity network fusion (SNF) subtypes by artificial intelligence-assisted classification and randomly assigned to receive subtyping-based precision therapy (N = 70) or treatment of physician's choice (N = 35). Results demonstrate superior primary endpoint of objective response rates in the subtyping-based groups compared to controls: 10% versus 0% for SNF1, 65% versus 30% for SNF2, 40% versus 30% for SNF3, and 70% versus 20% for SNF4. Grade 3-4 treatment-related adverse events occurred in 37% of both groups. These findings highlight the clinical benefits of subtyping-based precision therapies, particularly for SNF2 and SNF4 subtypes, warranting further validation in phase III trials.
KM 提取结果
0 个 Figure · 0 个 KM 面板